Unknown

Dataset Information

0

Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.


ABSTRACT: Fifteen patients with treatment-refractory colorectal cancer were enrolled on a phase 1b study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia designed to selectively replicate in cancer cells. Pexa-Vec was administered intravenously every 14 days, at dose levels of 1?×?10(6), 1?×?10(7), or 3?×?10(7) plaque-forming units (pfu)/kg. The primary endpoint was to determine the maximum tolerated dose. Secondary endpoints were pharmacokinetics and pharmacodynamics as well as antitumor activity. Patients were heavily pretreated (mean 4.5 lines of therapy). All patients received at least two Pexa-Vec doses (median = 4; range = 2-4). No dose-limiting toxicities were reported, and the maximum tolerated dose was not reached. The most common adverse events were grade 1/2 flu-like symptoms, generally lasting <24 hours. During the first and last cycles, genome pharmacokinetics were unchanged. Infectious pfu could be detected in plasma up to 2 hours after cycle 1 and up to 30 minutes after cycle 4 (when antivaccinia antibody titers are known to have peaked). Ten patients (67%) had radiographically stable disease. Given the acceptable safety profile of multiple intravenous Pexa-Vec infusions in patients with treatment-refractory colorectal cancer, further trials evaluating efficacy of intravenous Pexa-Vec, as monotherapy or in combination with chemotherapeutic agents, is warranted in this patient population.

SUBMITTER: Park SH 

PROVIDER: S-EPMC4817877 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.

Park Se Hoon SH   Breitbach Caroline J CJ   Lee Jeeyun J   Park Joon Oh JO   Lim Ho Yeong HY   Kang Won Ki WK   Moon Anne A   Mun Jae-Hee JH   Sommermann Erica M EM   Maruri Avidal Liliana L   Patt Rick R   Pelusio Adina A   Burke James J   Hwang Tae-Ho TH   Kirn David D   Park Young Suk YS  

Molecular therapy : the journal of the American Society of Gene Therapy 20150615 9


Fifteen patients with treatment-refractory colorectal cancer were enrolled on a phase 1b study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia designed to selectively replicate in cancer cells. Pexa-Vec was administered intravenously every 14 days, at dose levels of 1 × 10(6), 1 × 10(7), or 3 × 10(7) plaque-forming units (pfu)/kg. The primary endpoint was to determine the maximum tolerated dose. Secondary endpoints were pharmacokinetics and pharmacod  ...[more]

Similar Datasets

| S-EPMC4351466 | biostudies-literature
| S-EPMC4268543 | biostudies-literature
| S-EPMC9724410 | biostudies-literature
| S-EPMC11095598 | biostudies-literature
| S-EPMC3540938 | biostudies-literature
| S-EPMC2990519 | biostudies-other
| S-EPMC3321594 | biostudies-literature
| S-EPMC3188739 | biostudies-literature
| S-EPMC3129795 | biostudies-literature
| S-EPMC3621142 | biostudies-literature